Delivery of inhalation drugs to children for asthma and other respiratory diseases

Advanced Drug Delivery Reviews

Volumn 73, Issue , 2014, Pages 83-88

  Kwok, Philip Chi Lip ^a   Chan, Hak Kim ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Aerosol; Airways; Deposition; Dry powder inhaler; Lungs; Metered dose inhaler; Nebuliser; Paediatric; Spacer; Throat

Indexed keywords

AEROSOLS; AIR TRANSPORTATION; DEPOSITION; DRUG PRODUCTS;

DRY POWDER INHALER; LUNGS; METERED-DOSE INHALERS; NEBULISER; SPACER; THROAT;

PEDIATRICS;

AGE; ASTHMA; CHILD; DRUG DELIVERY SYSTEM; DRY POWDER INHALER; FACE MASK; HUMAN; INHALATION SPACER; MATHEMATICAL COMPUTING; METERED DOSE INHALER; NEBULIZER; PARTICLE DEPOSITION; PARTICLE SIZE; PHYSICAL PHENOMENA; PRIORITY JOURNAL; REVIEW; SOFT MIST INHALER; AEROSOL; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; PEDIATRICS; RESPIRATORY SYSTEM; RESPIRATORY TRACT DISEASES; BREATHING PATTERN; COMPUTATIONAL FLUID DYNAMICS; FLOW RATE; OFF LABEL DRUG USE; RESPIRATORY TRACT DISEASE; TIDAL VOLUME; UNLICENSED DRUG USE;

AEROSOL; RESPIRATORY TRACT AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; FENOTEROL PLUS IPRATROPIUM BROMIDE; SALBUTAMOL;

ADMINISTRATION, INHALATION; AEROSOLS; CHILD; HUMANS; NEBULIZERS AND VAPORIZERS; PEDIATRICS; RESPIRATORY SYSTEM; RESPIRATORY SYSTEM AGENTS; RESPIRATORY TRACT DISEASES;

EID: 84902343133     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.11.007     Document Type: Review

References (64)

1. Gillis J., Loughlan P. Not just small adults: the metaphors of paediatrics. Arch. Dis. Child. 2007, 92:946-947.
2. Food and Drugs Administration Providing Information about Pediatric Uses of Medical Devices under Section 515A of the Federal Food, Drug, and Cosmetic Act 2013, Food and Drugs Administration, Rockville, MD.
3. European Agency for the Evaluation of Medicinal Products Note for Guidance on Clinical Investigation of Medicinal Products in the Paediatric Population (CPMP/ICH/2711/99) 2000, European Agency for the Evaluation of Medicinal Products, London, UK.
4. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Clinical Investigation of Medicinal Products in the Pediatric Population E11. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland 2000.
5. World Health Organisation Paediatric Age Categories to be Used in Differentiating Between Listing on a Model Essential Medicines List for Children 2007, World Health Organisation, Geneva, Switzerland.
6. White I. Voting Age - Commons Library Standard Note SN/PC/1747 2013, House of Commons, London, UK.
7. Hinds W.C. Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles 1999, John Wiley & Sons, New York, NY.
8. Finlay W.H. The Mechanics of Inhaled Pharmaceutical Aerosols: an Introduction 2001, Academic Press, London, UK.
9. Hofmann W. Mathematical model for the postnatal growth of the human lung. Respir. Physiol. 1982, 49:115-129.
10. Xu G.B., Yu C.P. Effects of age on deposition of inhaled aerosols in the human lung. Aerosol Sci. Technol. 1986, 5:349-357.
11. Phalen R.F., Oldham M.J., Beaucage C.B., Crocker T.T., Mortensen J.D. Postnatal enlargement of human tracheobronchial airways and implications for particle deposition. Anat. Rec. 1985, 212:368-380.
12. Hofmann W., Martonen T.B., Graham R.C. Predicted deposition of nonhygroscopic aerosols in the human lung as a function of subject age. J. Aerosol Med. 1989, 2:49-68.
13. Yu C.P., Zhang L., Becquemin M.H., Roy M., Bouchikhi A. Algebraic modeling of total and regional deposition of inhaled particles in the human lung of various ages. J. Aerosol Sci. 1992, 23:73-79.
14. Segal R.A., Guan X., Shearer M., Martonen T.B. Mathematical model of airflow in the lungs of children I: effects of tumor sizes and locations. J. Theor. Med. 2000, 2:199-213.
15. Guan X., Segal R.A., Shearer M., Martonen T.B. Mathematical model of a airflow in the lungs of children II: effects of ventilatory parameters. J. Theor. Med. 2000, 3:51-62.
16. Longest P.W., Vinchurkar S., Martonen T. Transport and deposition of respiratory aerosols in models of childhood asthma. J. Aerosol Sci. 2006, 37:1234-1257.
17. Longest P.W., Vinchurkar S. Inertial deposition of aerosols in bifurcating models during steady expiratory flow. J. Aerosol Sci. 2009, 40:370-378.
18. Schiller-Scotland C.F., Hlawa R., Gebhart J. Experimental data for total deposition in the respiratory tract of children. Toxicol. Lett. 1994, 72:137-144.
19. Devadason S.G., Huang T., Walker S., Troedson R., Le Souëf P.N. Distribution of technetium-99m-labelled QVAR™ delivered using an Autohaler™ device in children. Eur. Respir. J. 2003, 21:1007-1011.
20. Roller C.M., Zhang G., Troedson R.G., Leach C.L., Le Souëf P.N. Spacer inhalation technique and deposition of extrafine aerosol in asthmatic children. Eur. Respir. J. 2007, 29:299-306.
21. Chua H.L., Collis G.G., Newbury A.M., Chan K., Bower G.D., Sly P.D., Le Souef P.N. The influence of age on aerosol deposition in children with cystic fibrosis. Eur. Respir. J. 1994, 7:2185-2191.
22. Wildhaber J.H., Dore N.D., Wilson J.M., Devadason S.G., Le Souef P.N. Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J. Pediatr. 1999, 135:28-33.
23. Chrystyn H. Anatomy and physiology in delivery: can we define our targets?. Allergy 1999, 49:82-87.
24. Dolovich M. Aerosol delivery to children: what to use, how to choose. Pediatr. Pulmonol. 1999, 27(Supplement 18):79-82.
25. Mallol J., Rattray S., Walker G., Cook D., Robertson C.F. Aerosol deposition in infants with cystic fibrosis. Pediatr. Pulmonol. 1996, 21:276-281.
26. Tal A., Golan H., Grauer N., Aviram M., Albin D., Quastel M.R. Deposition pattern of radiolabeled salbutamol inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction. J. Pediatr. 1996, 128:479-484.
27. Schüepp K.G., Devadason S., Roller C., Wildhaber J.H. A complementary combination of delivery device and drug formulation for inhalation therapy in preschool children. Swiss Med. Wkly. 2004, 134:198-200.
28. Amirav I., Balanov I., Gorenberg M., Luder A.S., Newhouse M.T., Groshar D. β-agonist aerosol distribution in respiratory syncytial virus bronchiolitis in infants. J. Nucl. Med. 2002, 43:487-491.
29. Diot P., Palmer L.B., Smaldone A., DeCelie-Germana J., Grimson R., Smaldone G. RhDNase I aerosol deposition and related factors in cystic fibrosis. Am. J. Respir. Crit. Care Med. 1997, 156:1662-1668.
30. Devadason S.G., Everard M.L., MacEarlan C., Roller C., Summers Q.A., Swift P., Borgstrom L., Le Souëf P.N. Lung deposition from the Turbuhaler® in children with cystic fibrosis. Eur. Respir. J. 1997, 10:2023-2028.
31. Nerbrink O.L., Lindström M., Meurling L., Svartengren M. Inhalation and deposition of nebulized sodium cromoglycate in two different particle size distributions in children with asthma. Pediatr. Pulmonol. 2002, 34:351-360.
32. Schuh S., Johnson D.W., Stephens D., Callahan S., Winders P., Canny G.J. Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma. J. Pediatr. 1999, 135:22-27.
33. Salmon B., Wilson N.M., Silverman M. How much aerosol reaches the lungs in wheezy infants and toddlers?. Arch. Dis. Child. 1990, 65:401-403.
34. Fok T.F., Monkman S., Dolovich M., Gray S., Coates G., Paes B., Rashid F., Newhouse M., Kirpalani H. Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Pediatr. Pulmonol. 1996, 21:301-309.
35. Everard M.L. Inhalation therapy in infants. Adv. Drug Deliv. Rev. 2003, 55:869-878.
36. Fink J.B. Delivery of inhaled drugs for infants and small children: a commentary on present and future needs. Clin. Ther. 2012, 34:S36-S45.
37. Smyth A.R., Barbato A., Beydon N., Bisgaard H., de Boeck K., Brand P., Bush A., Fauroux B., de Jongste J., Korppi M., O'Callaghan C., Pijnenburg M., Ratjen F., Southern K., Spencer D., Thomson A., Vyas H., Warris A., Merkus P.J. Respiratory medicines for children: current evidence, unlicensed use and research priorities. Eur. Respir. J. 2010, 35:247-265.
38. O'Callaghan C., White J., Jackson J., Barry P.W., Kantar A. Delivery of nebulized budesonide is affected by nebulizer type and breathing pattern. J. Pharm. Pharmacol. 2005, 57:787-790.
39. Barry P.W., O'Callaghan C. An in vitro analysis of the output of budesonide from different nebulizers. J. Allergy Clin. Immunol. 1999, 104:1168-1173.
40. 2 agonist. J. Pharm. Pharmacol. 2008, 60:601-605.
41. Finlay W.H., Zuberbuhler P. In vitro comparison of belomethasone and salbutamol metered-dose inhaler aerosol inhaled during pediatric tidal breathing from four valved holding chambers. Chest 1998, 114:1676-1680.
42. Finlay W.H. Inertial sizing of aerosol inhaled during pediatric tidal breathing from an MDI with attached holding chamber. Int. J. Pharm. 1998, 168:147-152.
43. Cunningham S.J., Crain E.F. Reduction of morbidity in asthmatic children given a spacer device. Chest 1994, 106:753-757.
44. Lin Y.-Z., Hsieh K.-H. Metered dose inhaler and nebuliser in acute asthma. Arch. Dis. Child. 1995, 72:214-218.
45. Parkin P.C., Saunders N.R., Diamond S.A., Winders P.M., Macarthur C. Randomised trial spacer v nebuliser for acute asthma. Arch. Dis. Child. 1995, 72:239-240.
46. Erzinger S., Schueepp K.G., Brooks-Wildhaber J., Devadason S.G., Wildhaber J.H. Facemasks and aerosol delivery in vivo. J. Aerosol Med. 2007, 20:S78-S84.
47. Nikander K., Berg E., Smaldone G.C. Jet nebulizers versus pressurized metered dose inhalers with valved holding chambers: effects of the facemask on aerosol delivery. J. Aerosol Med. 2007, 20:S46-S58.
48. Smaldone G.C., Sangwan S., Shah A. Facemask design, facial deposition, and delivered dose of nebulized aerosols. J. Aerosol Med. 2007, 20:S66-S77.
49. Kundoor V., Dalby R.N. Assessment of facial and ocular deposition of nebulized aerosol using a color-based method. Drug Dev. Ind. Pharm. 2010, 36:1281-1285.
50. Janssens H.M., Tiddens H.A.W.M. Facemasks and aerosol delivery by metered dose inhaler-valved holding chamber in young children: a tight seal makes the difference. J. Aerosol Med. 2007, 20:S59-S65.
51. Morton R.W., Mitchell J.P. Design of facemasks for delivery of aerosol-based medication via pressurized metered dose inhaler with valved holding chamber: key issues that affect performance. J. Aerosol Med. 2007, 20:S29-S45.
52. Agertoft L., Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch. Dis. Child. 1993, 69:130-133.
53. Nielsen K.G., Auk I.L., Bojsen K., Ifversen M., Klug B., Bisgaard H. Clinical effect of Diskus™ dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children. Eur. Respir. J. 1998, 11:350-354.
54. von Berg A., Jeena P.M., Soemantri P.A., Vertruyen A., Schmidt P., Gerken F., Razzouk H. Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat® Soft Mist™ inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma. Pediatr. Pulmonol. 2004, 37:264-272.
55. Storey-Bishoff J., Noga M., Finlay W.H. Deposition ofmicrometer-sized aerosol particles in infant nasal airway replicas. J. Aerosol Sci. 2008, 39:1055-1065.
56. Golshani L., Noga M.L., Thompson R.B., Finlay W.H. In vitro deposition measurement of inhaled micrometer-sized particles in extrathoracic airways of children and adolescents during nose breathing. J. Aerosol Sci. 2011, 42:474-488.
57. Janssens H.M., de Jongste J.C., Fokkens W.J., Robben S.G.F., Wouters K., Tiddens H.A.W.M. The Sophia Anatomical Infant Nose-Throat (SAINT) model: a valuable tool to study aerosol deposition in infants. J. Aerosol Med. 2001, 14:433-441.
58. Laube B.L., Sharpless G., Shermer C., Nasir O., Sullivan V., Powell K. Deposition of albuterol aerosol generated by pneumatic nebulizer in the Sophia Anatomical Infant Nose-Throat (SAINT) model. Pharm. Res. 2010, 27:1722-1729.
59. Corcoran T.E., Shortall B.P., Kim I.K., Meza M.P., Chigier N. Aerosol drug delivery using heliox and nebulizer reservoirs: results from an MRI-based pediatric model. J. Aerosol Med. 2003, 16:263-271.
60. Minocchieri S., Burren J.M., Bachmann M.A., Stern G., Wildhaber J., Buob S., Schindel R., Kraemer R., Frey U.P., Nelle M. Development of the Premature Infant Nose Throat-Model (PrINT-Model) - an upper airway replica of a premature neonate for the study of aerosol delivery. Pediatr. Res. 2008, 64:141-146.
61. Golshani L., Noga M.L., Finlay W.H. Deposition of inhaled micrometer-sized particles in oropharyngeal airway replicas of children at constant flow rates. J. Aerosol Sci. 2012, 49:21-31.
62. Stapleton K.W., Guentsch E., Hoskinson M.K., Finlay W.H. On the suitability of k-ε turbulence modeling for aerosol deposition in the mouth and throat: a comparison with experiment. J. Aerosol Sci. 2000, 31:739-749.
63. Golshani L., Finlay W.H. An idealized child throat that mimics average pediatric oropharyngeal deposition. Aerosol Sci. Technol. 2012, 46:i-iv.
64. Below A., Bickmann D., Breitkreutz J. Assessing the performance of two dry powder inhalers in preschool children using an idealized pediatric upper airway model. Int. J. Pharm. 2013, 444:169-174.